Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24434739 | 1.00 | KMT2A (0.50) | KMT2AP2RX7MEN1MMP2ANPEP | |
| SCHEMBL631143 | 1.00 | KMT2A (0.50) | KMT2AP2RX7MEN1MMP2ANPEP | |
| SCHEMBL31439851 | 0.85 | CNR2 (0.54) | P2RX7MMP2CA1CA2CA4 | |
| SCHEMBL9032092 | 0.85 | TDP1 (0.52) | KMT2AP2RX7MEN1CA1CA2 | |
| SCHEMBL9341749 | 0.85 | KDM4E (0.41) | KMT2AP2RX7MEN1HDAC6 | |
| SCHEMBL630463 | 0.82 | P2RX7 (0.51) | KMT2AP2RX7MEN1MMP2PHGDH | |
| SCHEMBL289664 | 0.82 | P2RX7 (0.51) | KMT2AP2RX7MEN1MMP2PHGDH | |
| SCHEMBL289579 | 0.82 | P2RX7 (0.51) | KMT2AP2RX7MEN1MMP2PHGDH | |
| SCHEMBL10563487 | 0.81 | KMT2A (0.44) | KMT2AP2RX7MEN1ALDH1A1 | |
| SCHEMBL19974671 | 0.80 | P2RX7 (0.49) | KMT2AP2RX7MEN1MMP2PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824465-B | Method for synthesizing amide by amine oxide catalyzed by bipyridine manganese catalyst | 陕西师范大学 | 2022-01-04 | — | — | CN | disclosed |
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2049478-B1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8048907-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2011-11-01 | — | — | US | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| EP-2049478-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | KMT2A 802/4885P2RX7 3565/4885MEN1 3929/4885 |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | KMT2A 4700/4885P2RX7 1/4885MEN1 4860/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | KMT2A 4700/4885P2RX7 1/4885MEN1 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.